LOS ANGELES--(BUSINESS WIRE)--A cancer-suppressing gene has been successfully delivered into the tumors of stage IV lung cancer patients via Introgen Therapeutics, Inc.’s (NASDAQ:INGN) intravenously administered lipid nanoparticle product candidate INGN 401. In a phase 1 clinical trial conducted at The University of Texas M. D. Anderson Cancer Center, the gene, FUS1, was found to be active in patients’ metastatic non-small cell lung cancer tumors.